Watch SLXNW. Know when insiders buy.
One email the day a filing lands. Free.
SLXNW
Silexion Therapeutics Corp
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
33
FLAG · shorts 33
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$14MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.7M | −$3.6M | — | 5.17 | −$2.9M | $0 | −$2.9M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$2.7M | −$2.7M | — | 0.85 | −$3.6M | $0 | −$3.6M | May 15 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.4M | −$4.4M | — | -1.40 | −$3M | $2K | −$3M | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | −$3.3M | −$3.3M | — | 2.88 | −$2.8M | $0 | −$2.8M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$2.3M | −$2.5M | — | 43.19 | −$2.5M | $1K | −$2.5M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$1.6M | −$1.7M | — | 3.84 | −$2.5M | $6K | −$2.5M | May 15 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.9M | −$1.7M | — | -359.91 | −$2.9M | $0 | −$2.9M | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$8M | −$11.9M | — | 274.25 | −$2.7M | $16K | −$2.7M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$1.4M | −$1.5M | — | 197.80 | −$1.1M | $0 | −$1.1M | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$1.3M | −$1.4M | — | 12.29 | −$1.8M | $6K | −$1.8M | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.7M | −$1.7M | — | 41.03 | −$1.3M | $4K | −$1.3M | Mar 18 |
| Q3 2023 · Sep 30 | — | — | — | −$731K | −$809K | — | 0.78 | −$685K | $6K | −$691K | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$11.6M | −$11.9M | — | 8.96 | −$10.8M | $9K | −$10.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$12.6M | −$16.5M | — | 394.94 | −$8.4M | $22K | −$8.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$4.7M | −$5.1M | — | 44.23 | −$4.5M | $12K | −$4.5M | — | — |
Every number comes from Silexion Therapeutics Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.